CareLit · DOI-Nachweis · TumorDiagnostik & Therapie
Treatment of high-risk MDS patients: State of the art
DOI 10.1055/s-0034-1389172
Bibliografische Angaben
Nachweis in CareLit
Autor:innenM Lübbert
ZeitschriftTumorDiagnostik & Therapie
Ausgabe10/2014
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
The treatment options for high-risk MDS patients, whether non-curative (due to age, comorbidities, reduced performance status etc.) or curative (because of a viable option of allogeneic stem cell transplantation) have clearly grown recently. 5-azacytidine (Vidaza, 5-aza) was FDA- and EMA-approved for the treatment of MDS (EMA: IPSS higher-risk) and patients with 20–30% blasts (formerly categorized as MDS RAEB-t, AML…
Zitieren
Zitierempfehlung
M Lübbert (2014) Treatment of high-risk MDS patients: State of the art. TumorDiagnostik & Therapie (10). https://doi.org/10.1055/s-0034-1389172
Mit CareLit weiterarbeiten